Department of Health and Human Services July 28, 2016 – Federal Register Recent Federal Regulation Documents

Medicare Program; Request for an Exception to the Prohibition on Expansion of Facility Capacity Under the Hospital Ownership and Rural Provider Exceptions to the Physician Self-Referral Prohibition
Document Number: 2016-17928
Type: Notice
Date: 2016-07-28
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
The Social Security Act prohibits a physician-owned hospital from expanding its facility capacity, unless the Secretary of the Department of Health and Human Services (the Secretary) grants the hospital's request for an exception to that prohibition after considering input on the hospital's request from individuals and entities in the community where the hospital is located. The Centers for Medicare & Medicaid Services (CMS) has received a request from a physician-owned hospital for an exception to the prohibition against expansion of facility capacity. This notice solicits comments on the request from individuals and entities in the community in which the physician-owned hospital is located. Community input may inform our determination regarding whether the requesting hospital qualifies for an exception to the prohibition against expansion of facility capacity.
Notice of Opportunity for Hearing on Compliance of Arkansas State Plan Provisions Concerning Provision of Benefits During a Reasonable Opportunity Period With Titles XI and XIX (Medicaid) of the Social Security Act
Document Number: 2016-17923
Type: Notice
Date: 2016-07-28
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Department of Health and Human Services (hhs)
Prescription Drug User Fee Rates for Fiscal Year 2017
Document Number: 2016-17870
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the rates for prescription drug user fees for fiscal year (FY) 2017. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2012 (PDUFA V), authorizes FDA to collect user fees for certain applications for the review of human drug and biological products, on establishments where the products are made, and on such products. This notice establishes the fee rates for FY 2017.
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: 2016-17867
Type: Notice
Date: 2016-07-28
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Oncologic Drugs Advisory Committee; Notice of Meeting
Document Number: 2016-17865
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.
Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting
Document Number: 2016-17864
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The general function of the committees is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.
Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2017
Document Number: 2016-17848
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the rates and payment procedures for fiscal year (FY) 2017 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Animal Drug User Fee Amendments of 2013 (ADUFA III), authorizes FDA to collect user fees for certain animal drug applications and supplements, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2017.
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review; Cancelation
Document Number: 2016-17827
Type: Notice
Date: 2016-07-28
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
This meeting was announced in the Federal Register on July 14, 2016, 81 FR 45506. This meeting is canceled in its entirety.
Board of Scientific Counselors, Office of Public Health Preparedness and Response; Meetings
Document Number: 2016-17826
Type: Notice
Date: 2016-07-28
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Animal Generic Drug User Fee Rates and Payment Procedures for Fiscal Year 2017
Document Number: 2016-17811
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the fee rates and payment procedures for fiscal year (FY) 2017 generic new animal drug user fees. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2013 (AGDUFA II), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, and for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs. This notice establishes the fee rates for FY 2017.
National Cancer Institute Notice of Closed Meetings
Document Number: 2016-17810
Type: Notice
Date: 2016-07-28
Agency: Department of Health and Human Services, National Institutes of Health
Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Establishment of a Public Docket; Request for Comments
Document Number: 2016-17804
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is establishing a public docket for comment on the Agency's blood donor deferral recommendations for reducing the risk of human immunodeficiency virus (HIV) transmission as described in the document entitled ``Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry'' dated December 2015. Interested persons are invited to submit comments, supported by scientific evidence such as data from research, regarding potential blood donor deferral policy options to reduce the risk of HIV transmission, including the feasibility of moving from the existing time-based deferrals related to risk behaviors to alternate deferral options, such as the use of individual risk assessments. Additionally, comments are invited regarding the design of potential studies to evaluate the feasibility and effectiveness of such alternative deferral options. FDA will take the comments received into account as it continues to reevaluate and update blood donor deferral policies as new scientific information becomes available.
Agency Information Collection Activities; Proposed Collection; Comment Request; Pre-Submission Program for Medical Devices
Document Number: 2016-17802
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on requests for feedback submitted under the Pre-Submission program for medical devices.
Biosimilar User Fee Rates for Fiscal Year 2017
Document Number: 2016-17800
Type: Notice
Date: 2016-07-28
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the rates for biosimilar user fees for fiscal year (FY) 2017. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Biosimilar User Fee Act of 2012 (BsUFA), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development, certain applications and supplements for approval of biosimilar biological products, establishments where approved biosimilar biological products are made, and a biosimilar biological product fee for each biosimilar biological product approved in a biosimilar biological product application. BsUFA directs FDA to establish, before the beginning of each fiscal year, the initial and annual biosimilar biological product development (BPD) fees, the reactivation fee, and the biosimilar biological product application, establishment, and product fees. These fees are effective on October 1, 2016, and will remain in effect through September 30, 2017.
National Center for Chronic Disease Prevention and Health Promotion, Interagency Committee on Smoking and Health (ICSH)
Document Number: 2016-17799
Type: Notice
Date: 2016-07-28
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)-Advisory Council for the Elimination of Tuberculosis (ACET)
Document Number: 2016-17795
Type: Notice
Date: 2016-07-28
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Request for Nominations of Candidates To Serve on the Advisory Committee to the Director, Centers for Disease Control and Prevention (ACD, CDC)
Document Number: 2016-17794
Type: Notice
Date: 2016-07-28
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services